--- canonical_name: "Dasatinib & Quercetin" alternate_names: D+Q, DQ, Dasatinib plus Quercetin, Dasatinib and Quercetin canonical_topic: "Dasatinib & Quercetin as a Senolytic Therapy" short_topic_lc: dasatinib_quercetin_senolytic creation_date: 2026-0810-0107 creator_ai_fullname: Grok 4 --- # Dasatinib & Quercetin as a Senolytic Therapy
Evidence Review created on 08/10/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4 **Also known as:** D+Q, DQ, Dasatinib plus Quercetin, Dasatinib and Quercetin ## Motivation Dasatinib and quercetin form a two-drug combination studied as a senolytic therapy—an approach that aims to selectively clear senescent cells. Senescent cells have stopped dividing yet remain metabolically active and release inflammatory signals that can damage nearby tissue. Dasatinib is a prescription tyrosine kinase inhibitor approved for certain leukemias; quercetin is a plant flavonoid found in onions, apples, and many supplements. Together they target different survival pathways that keep senescent cells alive, so the pair can clear a broader range of these cells than either agent alone. Interest grew after 2015 laboratory work showed selective clearance of senescent cells in animals, with later mouse studies linking intermittent dosing to better physical function and longer remaining lifespan. Early human pilot trials in lung fibrosis, diabetic kidney disease, and mild cognitive impairment reported feasibility and signals of reduced senescent-cell markers, while larger controlled work remains limited and mixed. This review examines the evidence for and against dasatinib plus quercetin as a senolytic strategy for health and longevity-oriented adults: mechanisms, human and preclinical benefits, risks of a cancer drug used intermittently with a supplement, protocols used in research and practice, and open questions from ongoing trials. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level overviews and expert discussions of dasatinib plus quercetin as a senolytic combination. - [Quercetin](https://www.foundmyfitness.com/topics/quercetin) - Rhonda Patrick FoundMyFitness topic page covering quercetin’s senolytic role specifically in combination with dasatinib (often called DQ), including the diabetic kidney disease pilot that showed reduced senescent cells in adipose and skin. - [Targeting senescent cells for cognitive health](https://peterattiamd.com/senescent-cells-and-cognitive-health/) - Peter Attia Discusses D+Q as the best-characterized senolytic pair, the Gonzales phase 1 Alzheimer’s pilot (dosing, cerebrospinal fluid penetration of dasatinib), and why central nervous system penetration and efficacy remain open questions. - [Benefits of Senolytics](https://www.lifeextension.com/magazine/2021/2/senolytics) - Life Extension Magazine Accessible summary of early human D+Q data (including the three-day 100 mg dasatinib / 1,000 mg quercetin diabetic kidney disease protocol) and the broader senolytic concept for age-related decline. - [Results of a Phase 1 Trial of Senolytics for Alzheimer's](https://www.lifespan.io/results-of-a-phase-1-trial-of-senolytics-for-alzheimers/) - Josh Conway Critical write-up of a small D+Q Alzheimer’s phase 1 experience, emphasizing largely null effects on key amyloid and cognitive endpoints and the need for caution in interpreting early open-label work. - [Senolytic drugs: from discovery to translation](https://pubmed.ncbi.nlm.nih.gov/32686219/) - Kirkland & Tchkonia, 2020 Narrative review by the Mayo Clinic group that discovered D+Q; covers senescent cell anti-apoptotic pathways (SCAPs), intermittent “hit-and-run” dosing rationale, preclinical disease models, and the state of early human trials. No dedicated Andrew Huberman Lab episode or article focused on dasatinib plus quercetin was found; Huberman content mentions quercetin mainly in immune/zinc contexts. Chris Kresser discusses quercetin as a phytochemical with senolytic properties but not the D+Q combination in depth. ## Grokipedia - [Senolytic](https://grokipedia.com/page/Senolytic) Grokipedia’s primary article on senolytics frames dasatinib plus quercetin as the prototype combination from 2015 high-throughput screens, and summarizes intermittent dosing, early human pilots, and competing agents (fisetin, navitoclax). ## Examine No Examine.com article for dasatinib plus quercetin (D+Q) as a combined intervention was found. Examine.com does not typically cover prescription medications such as dasatinib; a separate [Quercetin](https://examine.com/supplements/quercetin/) supplement entry exists for the flavonoid alone. ## ConsumerLab No ConsumerLab review for dasatinib plus quercetin as a senolytic combination was found. ConsumerLab does not typically cover prescription medications such as dasatinib. Independent quality testing of the quercetin component is available in ConsumerLab’s [Quercetin & Rutin Supplements Review](https://www.consumerlab.com/reviews/quercetin-supplements/quercetin/). ## Systematic Reviews No systematic reviews or meta-analyses for Dasatinib & Quercetin were found on PubMed as of August 10, 2026. ## Mechanism of Action Senescent cells resist programmed cell death by up-regulating senescent cell anti-apoptotic pathways (SCAPs)—survival networks that protect them from their own inflammatory milieu. Dasatinib and quercetin disable different SCAPs, so the combination clears a wider range of senescent cell types than either drug alone. - **Dasatinib:** An oral multi-kinase inhibitor (brand Sprycel) that blocks BCR-ABL (the fusion kinase driving certain leukemias), SRC-family kinases, and related tyrosine kinases. In senescent cells it disrupts dependence receptor and ephrin-related survival signaling (including dependence on tyrosine kinases that keep pro-survival pathways active). Terminal plasma half-life is about 3–5 hours. It is primarily metabolized by CYP3A4 (the main liver enzyme that oxidizes many drugs); strong CYP3A4 inhibitors raise exposure and inducers lower it. Tissue distribution is broad; cerebrospinal fluid (CSF) levels in Alzheimer’s pilots were low but detectable for dasatinib in most participants. - **Quercetin:** A plant flavonol that inhibits anti-apoptotic BCL-2 family members (notably BCL-xL), PI3K/AKT (phosphoinositide 3-kinase / protein kinase B survival signaling), and other survival nodes more relevant to certain epithelial and endothelial senescent cells. Oral bioavailability of plain quercetin is modest; phytosome or other enhanced forms raise plasma levels. Elimination half-life is typically on the order of ~11–28 hours depending on formulation and individual metabolism, including phase II conjugation via UGTs and SULTs (liver enzymes that attach sugar or sulfate groups to clear the drug) with some CYP contribution. - **Complementarity and “hit-and-run”:** Because senescent cells take weeks to reaccumulate, intermittent short courses (often 2–3 consecutive days) can thin the burden without continuous kinase inhibition. Both agents have short enough half-lives that plasma exposure is largely cleared within a day or two after a dosing pulse. The combination is not selective for every senescent subtype; other senolytics (fisetin, navitoclax/BCL inhibitors, FOXO4-DRI peptides) target overlapping but non-identical populations. Competing views: some researchers argue measured reductions in p16/p21 markers or SASP (senescence-associated secretory phenotype) factors in small open-label studies could partly reflect non-senolytic anti-inflammatory effects of quercetin or transient marrow suppression from dasatinib rather than true selective clearance. Larger randomized trials with tissue endpoints are still needed to settle magnitude and durability in humans. ## Historical Context & Evolution Dasatinib was developed as a second-generation BCR-ABL tyrosine kinase inhibitor and approved for chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. Quercetin has long been studied as a dietary flavonoid with antioxidant and anti-inflammatory claims. In 2015, Zhu, Tchkonia, Kirkland and colleagues at Mayo Clinic published a hypothesis-driven screen of compounds targeting SCAPs and identified dasatinib and quercetin as the first drug-like senolytics with complementary spectra (*Aging Cell*, [PMID 25754370](https://pubmed.ncbi.nlm.nih.gov/25754370/)). Subsequent mouse work (including Xu et al. 2018, [PMID 29988130](https://pubmed.ncbi.nlm.nih.gov/29988130/)) reported that intermittent D+Q reduced senescent cell burden, improved physical function, and increased post-treatment survival in old mice by roughly a third in one key study. Translation to humans began with open-label pilots: idiopathic pulmonary fibrosis (IPF) feasibility (Justice et al. 2019), diabetic kidney disease with tissue biopsies (Hickson et al. 2019), and later Alzheimer’s disease feasibility (Gonzales et al. 2023). A randomized placebo-controlled IPF pilot (Nambiar et al. 2023) confirmed feasibility and tolerability but did not reproduce clear functional gains. A 2024 phase 2 bone randomized controlled trial (RCT) in postmenopausal women (Farr et al.) missed its primary resorption endpoint overall, with exploratory benefit concentrated in participants with higher baseline senescent burden. Opinion in the field has shifted from early enthusiasm about a general longevity drug toward a more measured view: D+Q is a useful research tool and a plausible intermittent therapy for selected senescence-associated conditions, but clinical efficacy is disease- and possibly biomarker-stratified, and long-term safety of repeated dasatinib pulses in non-oncology populations is not established. Parallel development of other senolytics (fisetin, BCL inhibitors, CAR-T (chimeric antigen receptor T-cell therapy) against senescent antigens) continues alongside D+Q trials. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit of dasatinib plus quercetin currently meets a High evidence grade in humans (multiple large, independent RCTs with consistent clinical endpoints). Available human data are early-phase, small, and often open-label. ### Medium 🟩 🟩 #### Reduction of senescent cell markers in human tissues In the open-label Hickson et al. pilot (n = 9 adults with diabetic kidney disease; 3 days of dasatinib 100 mg plus quercetin 1,000 mg), adipose and skin biopsies 11 days after dosing showed fewer p16^INK4A- and p21^CIP1-positive cells, less senescence-associated β-galactosidase activity, and lower circulating SASP factors (including IL-6 (interleukin-6), IL-1α (interleukin-1 alpha), and MMP-9/MMP-12 (matrix metalloproteinases involved in tissue remodeling)). This is direct human tissue evidence that a short D+Q pulse can reduce senescent cell markers, though the study had no placebo control and a tiny sample. **Magnitude:** Qualitative reduction in tissue p16/p21 and selected circulating SASP factors within ~11 days after a 3-day course (n = 9; open-label). #### Feasibility and short-term tolerability of intermittent D+Q in selected disease states Multiple pilot trials (IPF open-label and RCT; diabetic kidney disease; mild Alzheimer’s; bone health) completed planned intermittent dosing with high retention and no excess of treatment-related serious adverse events in short follow-up. This supports that the research protocol is operationally feasible under medical supervision, not that long-term net benefit is proven. **Magnitude:** Near-complete course completion in published pilots (e.g., 100% retention in Justice IPF open-label; full dose completion in Nambiar RCT); short-term serious adverse event (SAE) profile similar to background disease in small samples. ### Low 🟩 #### Physical function in idiopathic pulmonary fibrosis (open-label signal; not confirmed in RCT) ⚠️ Conflicted In the first-in-human open-label IPF pilot (Justice et al. 2019; n = 14; dasatinib 100 mg/day + quercetin 1,250 mg/day, 3 consecutive days per week for 3 weeks), 6-minute walk distance, 4-m gait speed, and chair-stand time improved in a clinically meaningful range, while pulmonary function tests were unchanged. The subsequent single-center randomized placebo-controlled pilot (Nambiar et al. 2023; n = 12) found intermittent D+Q feasible and generally tolerable but did not show meaningful between-group differences in frailty or physical function (underpowered). Functional benefit in IPF therefore remains unconfirmed. **Magnitude:** Open-label: statistically and clinically meaningful gains in walk distance and gait metrics; RCT pilot: no clear between-group functional difference (small n). #### Exploratory skeletal effects stratified by senescent burden Farr et al. 2024 (phase 2 RCT, n = 60 postmenopausal women) did not meet the primary endpoint of reduced bone resorption marker CTx (C-terminal telopeptide of type I collagen) at 20 weeks in the overall cohort. Exploratory analyses suggested that women in the highest tertile of T-cell p16 mRNA had early increases in formation marker P1NP (procollagen type I N-terminal propeptide), reductions in CTx, and a ~2.7% increase in radius bone mineral density at 20 weeks. This supports a biomarker-enrichment hypothesis rather than a general bone benefit. **Magnitude:** Overall primary endpoint null; highest p16 tertile exploratory: radius bone mineral density (BMD) +2.7% at 20 weeks (P = 0.004), with early formation/resorption shifts. #### Central nervous system exposure and biomarker shifts in early Alzheimer’s disease Gonzales et al. 2023 (phase 1, n = 5 early symptomatic Alzheimer’s disease (AD); intermittent oral D+Q for 12 weeks) detected dasatinib in CSF in 4/5 participants at low concentrations; quercetin was not detected in CSF. Treatment was well tolerated; cognitive and imaging endpoints did not change significantly. CSF IL-6 and GFAP (glial fibrillary acidic protein, an astrocyte injury marker) rose, with mixed trends in other markers. Central nervous system (CNS) engagement of dasatinib is supported; clinical efficacy is not. **Magnitude:** CSF dasatinib present at ~0.4–0.9% of plasma levels in most participants; no significant cognitive or imaging change in this pilot. ### Speculative 🟨 #### Broader healthspan and multi-morbidity risk reduction in otherwise healthy aging adults Mouse data (including Xu et al. 2018) show improved physical function and increased remaining lifespan after intermittent D+Q in old animals, and many disease models improve when senescent cells are cleared. Extrapolation to healthy longevity-oriented humans is unproven; no adequately powered longevity or multi-morbidity outcome trial exists. #### Improved fracture healing, intervertebral disc integrity, metabolic function, and post-viral resilience Preclinical literature reports benefits in bone healing, disc degeneration, obesity-related metabolic dysfunction, and coronavirus-related mortality in old mice. Human confirmation for these endpoints is absent or only tangential. ## Benefit-Modifying Factors - **Baseline senescent cell burden:** Exploratory bone-trial data suggest greater skeletal response in postmenopausal women with higher T-cell p16 expression; people with low senescence load may see little measurable benefit. - **Age:** Most human pilots enroll older adults with established senescence-associated disease (IPF, CKD (chronic kidney disease), early AD). Younger healthy adults have lower senescent burdens; absolute benefit is expected to be smaller and is unstudied. - **Sex:** Limited human stratification. Preclinical reports of sexually dimorphic metabolic and cognitive responses to D+Q or related senolytics exist; human sex differences for D+Q remain poorly characterized. - **Disease context:** Signals (tissue marker reduction, open-label function) appear in high-senescence conditions (IPF, diabetic kidney disease). General “wellness” use lacks outcome data. - **Genetic and metabolic modifiers of drug levels:** CYP3A4 activity strongly affects dasatinib exposure; UGT/SULT and gut factors affect quercetin bioavailability. Variants or co-medications that alter these pathways can change both efficacy and toxicity risk. - **Formulation of quercetin:** Enhanced-bioavailability forms (e.g., phytosome) raise plasma quercetin versus plain powder; trials often used high-dose standard quercetin (1,000–1,250 mg/day on dosing days). ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Dasatinib-class adverse effects at oncology doses and schedules (label-level) FDA prescribing information for dasatinib (Sprycel) lists myelosuppression (bone-marrow suppression that lowers blood cell counts—including neutropenia (low neutrophils), thrombocytopenia (low platelets), and anemia), bleeding, fluid retention including pleural effusion (fluid around the lungs), pulmonary arterial hypertension (high blood pressure in the lung arteries), cardiovascular ischemia (inadequate blood flow to the heart) and conduction abnormalities (faulty electrical signaling in the heart), QT prolongation (a heart-rhythm interval change that can raise arrhythmia risk), severe dermatologic reactions, and embryo-fetal toxicity (harm to a developing embryo or fetus). These are established for continuous or near-continuous oncology use; intermittent low cumulative-dose longevity protocols use far less drug but are not free of the same mechanisms. **Magnitude:** Common in oncology populations (e.g., fluid retention events including pleural effusion in a substantial minority on continuous therapy; myelosuppression frequent). Rate under intermittent senolytic schedules is much lower in small pilots but not zero-risk. ### Medium 🟥 🟥 #### Gastrointestinal symptoms, headache, fatigue, rash, and respiratory complaints on intermittent D+Q In IPF pilots, non-serious adverse events (AEs) clustered around gastrointestinal (GI) discomfort, skin irritation/bruising, respiratory symptoms, sleep disturbance, and anxiety—partly overlapping background IPF and partly consistent with known dasatinib effects. Nambiar et al. reported more non-serious AEs on D+Q than placebo (including sleep/anxiety imbalance in a tiny sample). **Magnitude:** Majority of pilot participants reported at least mild AEs; serious treatment-related events were rare in published short pilots. #### Drug–drug interaction risk via CYP3A4 and QT/bleeding pathways Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin, grapefruit juice) can markedly raise dasatinib levels; strong inducers (e.g., rifampin, carbamazepine, St. John’s wort) can drop them. Combined use with anticoagulants/antiplatelets or QT-prolonging agents increases bleeding or arrhythmia concern. Quercetin can inhibit CYP3A4 and P-glycoprotein in vitro and may add interaction complexity. **Magnitude:** Clinically important interactions are well documented for dasatinib; quantitative interaction risk for intermittent senolytic courses depends on the co-medication list. ### Low 🟥 #### Transient effects on blood counts and inflammatory markers after a dosing pulse Even short courses can temporarily affect leukocyte lineages and circulating cytokines. Gonzales et al. observed rises in CSF IL-6 and GFAP after D+Q in AD participants—mechanistic interpretation unclear (clearance dynamics vs. irritation vs. other). Monitoring around dosing windows is used in trials for this reason. **Magnitude:** Usually mild and reversible in pilots; severe cytopenias (low blood cell counts) not characteristic of published intermittent regimens but remain a theoretical extension of dasatinib pharmacology. #### Off-target effects on non-senescent cells Senolytics are relatively selective, not absolutely specific. Concerns include effects on wound healing, beneficial senescence programs (e.g., tumor suppression, fibrosis limitation in some contexts), and—based on emerging animal data—possible adverse effects on myelin or oligodendrocyte function with certain D+Q schedules in aged rodents. Human relevance is unknown. **Magnitude:** Not quantified in available studies. ### Speculative 🟨 #### Long-term cumulative harm from repeated dasatinib pulses in non-cancer populations Repeated intermittent exposure over years (as some longevity protocols propose) has no long-term safety database. Theoretical risks include rare pleural/pericardial disease (fluid or inflammation around the lungs or heart), pulmonary hypertension, cardiac events, or selection pressures on hematopoietic clones. #### Harm from unregulated or self-directed sourcing of dasatinib Non-prescription acquisition of dasatinib (research chemical or overseas pharmacies) adds purity, dosing, and legal risks beyond pharmacology. Counterfeit or mislabeled product can deliver the wrong dose or contaminants, and intermittent “longevity” use outside supervised care lacks the lab monitoring built into trials. This concern is based on known quality failures in gray-market specialty drugs and regulatory warnings, not on controlled trials of illicit supply chains. ## Risk-Modifying Factors - **CYP3A4 genotype and phenotype:** Poor metabolizer–like states or strong inhibitors raise dasatinib exposure and toxicity risk; ultra-rapid/induced states may reduce senolytic pulse intensity. - **Baseline blood counts and marrow reserve:** Pre-existing cytopenias, recent chemotherapy, or marrow disorders amplify myelosuppression risk. - **Cardiovascular and pulmonary status:** Prior pleural effusion, pulmonary hypertension, heart failure, or significant ischemic disease increases concern for fluid retention and cardiopulmonary toxicity. - **Bleeding diathesis and antithrombotic use:** Concurrent anticoagulants, dual antiplatelet therapy, or bleeding disorders raise hemorrhage risk. - **Age and frailty:** Older adults are the intended senolytic population but also have less reserve for cytopenias, falls if dizzy/fatigued, and polypharmacy interactions. - **Sex and body size:** Oncology dosing is not fully weight-based for all scenarios; small-body-size older adults may experience relatively higher exposure at fixed 100 mg doses—data specific to senolytic schedules are sparse. - **Pregnancy and reproductive potential:** Dasatinib is embryo-fetal toxic; absolute avoidance in pregnancy and careful contraception planning apply. ## Key Interactions & Contraindications - **Strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, cobicistat, clarithromycin, grapefruit juice):** Severity — high caution / avoid or reduce dasatinib dose per oncology labeling logic. Consequence — elevated dasatinib exposure, higher risk of effusion, cytopenias, QT effects. Mitigation — avoid combination when possible; if unavoidable under specialist care, use lowest effective intermittent dose and intensify labs/electrocardiogram (ECG). - **Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort):** Severity — caution. Consequence — subtherapeutic dasatinib levels, possible loss of senolytic pulse. Mitigation — avoid inducers around dosing windows. - **Antacids and acid-reducing agents:** Severity — monitor / separate timing. Consequence — reduced dasatinib absorption if taken together. Mitigation — separate antacids by ≥2 hours; review PPIs/H2 blockers (proton-pump inhibitors and histamine-2 receptor blockers that reduce stomach acid) with prescriber. - **Anticoagulants and antiplatelets (warfarin, direct oral anticoagulants (DOACs), clopidogrel, aspirin at antiplatelet doses):** Severity — caution. Consequence — increased bleeding risk with dasatinib-associated platelet effects. Mitigation — specialist co-management; consider holding non-essential antiplatelets only if clinician directs. - **QT-prolonging drugs (certain antiarrhythmics, antipsychotics, macrolides):** Severity — caution. Consequence — additive arrhythmia risk. Mitigation — baseline and follow-up ECG if risk factors present. - **Other CYP3A4/P-gp (P-glycoprotein drug-transporter) substrate drugs:** Severity — monitor. Quercetin and dasatinib can alter exposure of sensitive substrates. Consequence — variable under- or over-exposure of companion drugs. - **Supplements with additive bleeding or CYP effects (high-dose fish oil, ginkgo, high-dose vitamin E, curcumin in some contexts):** Severity — mild–moderate caution. Consequence — theoretical bleeding or metabolic interaction. Mitigation — disclose full supplement list; simplify stack around dosing days. - **Other senolytics or cytotoxic agents (fisetin megadoses, navitoclax, chemotherapy):** Severity — avoid unsupervised stacking. Consequence — unpredictable additive cytopenias or tissue effects. - **Populations who should avoid (outside tightly supervised trials):** Pregnancy and breastfeeding; active uncontrolled infection; significant cytopenias; recent major surgery or non-healing wounds (senescence contributes to repair); known dasatinib hypersensitivity; severe hepatic impairment without specialist oversight; children/adolescents (except oncology indications). ## Risk Mitigation Strategies - **Medical supervision and prescription sourcing:** Use clinician-prescribed dasatinib (not research-chemical vendors). Mitigates purity, dosing, and unsupervised toxicity risk. - **Intermittent “hit-and-run” schedule rather than daily use:** Limit dasatinib to short pulses (e.g., 2–3 consecutive days) separated by weeks. Mitigates cumulative kinase-inhibitor toxicities while aligning with senescent-cell reaccumulation biology. - **Pre-course screening labs and history:** Complete blood count (CBC) with differential, comprehensive metabolic panel, ECG if cardiac risk, medication review for CYP3A4 and bleeding interactions. Mitigates preventable cytopenia, liver, and interaction events. - **Per-course monitoring:** Recheck CBC and symptoms (dyspnea (shortness of breath), edema, unusual bruising, fever) after early pulses. Mitigates delayed recognition of marrow or fluid-retention effects. - **Avoid strong CYP3A4 inhibitors/inducers and grapefruit around dosing days:** Stabilizes exposure. Mitigates accidental overdose or treatment failure. - **Hold or simplify elective supplements during dosing windows:** Reduces interaction noise. Mitigates bleeding and CYP-related surprises. - **Pulmonary symptom vigilance:** New or worsening dyspnea, dry cough, or chest discomfort prompts evaluation for effusion or pulmonary arterial hypertension (PAH)–spectrum issues. Mitigates rare but serious fluid-retention complications. - **Do not combine with elective surgery or major dental procedures in the immediate dosing window without surgeon clearance:** Mitigates bleeding and healing concerns. ## Therapeutic Protocol Protocols below reflect research and specialist practice patterns, not a universal standard of care. Dasatinib remains off-label for senolytic use. - **Common research pulse (IPF / general senolytic pilots):** Dasatinib 100 mg orally once daily + quercetin 1,000–1,250 mg/day (often split) on 3 consecutive days, repeated weekly for 3 weeks (Justice/Nambiar IPF pattern) or as a single 3-day pulse (Hickson diabetic kidney disease). - **Alzheimer’s / CNS-oriented pattern (Gonzales and related):** Dasatinib 100 mg + quercetin 1,000 mg intermittently (e.g., once every other week for several doses, or multi-week intermittent schedules totaling about six pulses in some protocols). Designed for feasibility and CNS penetration assessment more than proven cognitive efficacy. - **Bone health RCT pattern (Farr et al. 2024):** Intermittent D+Q over ~20 weeks in postmenopausal women (see trial record [NCT04313634](https://clinicaltrials.gov/study/NCT04313634) for exact schedule details used). - **Longevity-clinic “hit-and-run” variants:** Some integrative or longevity clinics adapt 2–3 consecutive dosing days every 1–3 months. These schedules are extrapolated from mouse reaccumulation kinetics and early human marker data; they are not validated by hard clinical outcome RCTs in healthy adults. - **Time of day:** Often taken in the morning with food per oncology counseling for GI tolerability; consistency matters more than a magic clock time. Avoid grapefruit products. - **Single vs split dose:** Dasatinib is typically once daily on dosing days (100 mg). Quercetin at 1,000–1,250 mg is frequently split (e.g., 2–3 doses) to improve GI tolerance. - **Half-life implications:** Dasatinib ~3–5 h terminal half-life; quercetin hours to ~1 day depending on form—supports pulse dosing without continuous steady-state kinase blockade. - **Genetics:** CYP3A4 interaction phenotype dominates practical dose safety more than common consumer SNPs (single-nucleotide polymorphisms—common single-letter DNA variants); formal pharmacogenetic testing is optional and not standardized for senolytic use. - **Sex and age:** Fixed 100 mg dasatinib pulses are used across older adult pilots of both sexes; extra caution in very low body weight, advanced frailty, or polypharmacy. - **Baseline biomarkers:** Higher senescence burden (research markers such as T-cell p16, SASP panels where available) may identify better candidates; not yet a validated clinical companion diagnostic. - **Pre-existing health conditions:** Active high-senescence disease (IPF, diabetic kidney disease, early AD) is the setting of most human pilots and may raise both the chance of a measurable response and the background risk of adverse events. Significant cytopenias, uncontrolled infection, recent major surgery or non-healing wounds, severe hepatic impairment, known dasatinib hypersensitivity, and pregnancy or breastfeeding are treated as reasons to avoid or tightly supervise use rather than routine protocol candidates. - **Competing approaches:** Fisetin-only intermittent protocols (supplement-only, different evidence base); navitoclax-class BCL inhibitors (more hematologic toxicity); lifestyle and exercise as non-drug modulators of senescent burden. Leading academic groups (Mayo Clinic Kirkland/Tchkonia; UT Health San Antonio; Wake Forest) popularized D+Q translational protocols. ## Discontinuation & Cycling - **Not a lifelong daily drug:** Designed as intermittent pulses; continuous daily D+Q is not the research model and would increase dasatinib toxicity risk without clear added senolytic benefit. - **No classic withdrawal syndrome:** Stopping after a pulse does not produce a recognized withdrawal state like opioids or chronic benzodiazepines. Senescent cells may gradually reaccumulate over weeks to months. - **Tapering:** Not typically required for short pulses of dasatinib; oncology tapers are a different context. Quercetin can be stopped abruptly. - **Cycling for maintenance:** Research logic supports repeating pulses only as often as senescent burden is expected to rebuild (often framed as monthly to quarterly in speculative longevity use). Evidence for an optimal re-treatment interval in healthy humans is weak; disease trials specify fixed short courses. - **When to stop permanently:** Intolerable AEs, serious fluid retention, significant cytopenias, pregnancy plans, or lack of individualized rationale under clinician review. ## Sourcing and Quality - **Dasatinib:** Obtain only via licensed prescription (brand Sprycel or approved generics). Verify pharmacy authenticity. Avoid “research chemical” and unverified overseas sources—purity, dose accuracy, and legal status are uncontrolled. - **Quercetin:** Prefer third-party tested supplements (USP, NSF, or ConsumerLab-verified brands when available). Enhanced-bioavailability forms (phytosome/liposomal) differ from bulk powder; match the form to the intended protocol and disclose it to the supervising clinician. - **Dose accuracy:** Human trials used pharmaceutical dasatinib tablets and defined quercetin milligram amounts; compounded or gray-market mixes introduce uncertainty. - **Storage:** Follow label (typically room temperature, dry). Quercetin powders can oxidize with heat, light, and moisture. - **Cost:** Generic dasatinib intermittent courses are far cheaper than continuous oncology therapy but still prescription-costly in some markets; quercetin is inexpensive. Access barriers are regulatory (off-label) more than raw ingredient cost for many. ## Practical Considerations - **Time to effect:** Tissue marker changes have been measured within ~11 days after a single 3-day pulse (Hickson). Functional changes, when reported, appeared over weeks. Durable clinical outcomes (if any) for healthy longevity use are unproven and would be expected on multi-month horizons. - **Common pitfalls:** Daily continuous dosing “for stronger effect”; stacking multiple senolytics without labs; buying dasatinib without medical oversight; ignoring CYP3A4 interactions (including grapefruit); expecting dramatic rejuvenation from one course; using quercetin alone and assuming equivalence to D+Q. - **Regulatory status:** Dasatinib is FDA-approved for specified leukemias; senolytic use is off-label. Quercetin is a dietary supplement (not FDA-approved to treat disease). Marketing senolytic “cures” for aging overstates the evidence. - **Cost and access:** Requires a prescribing clinician comfortable with off-label intermittent dasatinib and monitoring. Not universally available through conventional primary care. ## Interaction with Foundational Habits - **Sleep:** Direction — mixed/indirect. Dasatinib pulses can be associated with sleep disturbance or anxiety in some pilot participants; improved well-being from reduced inflammatory burden is theoretical. Practical: dose in the morning; avoid new stimulants on dosing days. - **Nutrition:** Direction — potentiating/interacting. Take with food if GI upset; avoid grapefruit and Seville orange products (CYP3A4). Adequate protein and micronutrients support recovery if mild cytopenias occur. Quercetin-rich foods do not replace pharmacologic quercetin doses used in trials. - **Exercise:** Direction — potentially potentiating for function. Exercise itself modulates senescence-related biology; D+Q is sometimes framed as complementary to training, not a substitute. Practical: maintain training but allow flexibility if fatigued or bruised on dosing days; avoid maximal eccentric damage experiments immediately after pulses until personal tolerance is known. - **Stress management:** Direction — indirect. No direct cortisol-pathway indication for D+Q. Illness anxiety about experimental protocols is real—clear monitoring plans reduce unnecessary stress. ## Monitoring Protocol & Defining Success Baseline evaluation before any course should include clinical history (cardiopulmonary, bleeding, medications), CBC with differential, comprehensive metabolic panel (liver and kidney), and ECG when cardiac risk factors or QT-interacting drugs are present. Research settings may add senescence-related biomarkers (e.g., T-cell p16 mRNA, selected SASP cytokines) where assays are available. Ongoing monitoring for intermittent users typically includes labs before and shortly after the first pulses, then periodically (e.g., around each course or every 3–6 months if repeating), plus prompt evaluation of dyspnea, edema, fever, or unusual bleeding. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | CBC with differential (WBC, ANC, hemoglobin, platelets) | Within age-appropriate lab reference; investigate any grade ≥2 cytopenia | Detect dasatinib-related marrow suppression | WBC = white blood cell count; ANC = absolute neutrophil count. Fasting not required; repeat after early pulses and if infection/bleeding symptoms | | Comprehensive metabolic panel (ALT/AST, bilirubin, creatinine/eGFR) | Liver enzymes near mid-normal; eGFR stable for the individual | Hepatic metabolism and renal comorbidity safety | ALT/AST = liver enzymes; eGFR = estimated glomerular filtration rate. Compare to personal baseline; dasatinib is not primarily renally cleared but chronic kidney disease is a common senolytic trial context | | ECG (QTc) | QTc within normal limits for sex; no new ischemic changes | Arrhythmia/ischemia risk screen | QTc = heart-rate–corrected QT interval on ECG. Baseline if cardiac risk or QT-interacting drugs; repeat if symptoms | | hs-CRP or selected inflammatory markers | Lower is generally better for residual risk context | Indirect inflammation context | hs-CRP = high-sensitivity C-reactive protein. Not a specific senescent-cell test; trends more useful than single values | | Research senescence markers (T-cell p16, SASP panel) when available | Lab-specific; higher burden may predict response (exploratory) | Stratify biological senescence load | Not standardized for clinical decision-making outside trials | **Qualitative markers:** - Energy and exercise tolerance over weeks after a pulse - Dyspnea, cough, peripheral edema, or rapid weight gain (fluid retention watch) - Bruising, bleeding gums, petechiae (tiny pinpoint red spots under the skin from minor bleeding) - Sleep quality and mood around dosing days - Subjective recovery after illness or training load (nonspecific) ## Emerging Research - **SToMP-AD and related AD programs:** Phase 2 [NCT04685590](https://clinicaltrials.gov/study/NCT04685590) (Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease; planned n ≈ 48; primary safety/AE endpoints) and related Phase 1/2 [NCT04785300](https://clinicaltrials.gov/study/NCT04785300) (ALSENLITE; planned n ≈ 20; safety and tolerability) test feasibility and early efficacy signals of D+Q in mild cognitive impairment (MCI)/early AD—critical because prior phase 1 work showed limited CSF quercetin and mixed biomarkers. - **Frailty and aging in special populations:** Phase 2 trials in HIV-associated frailty ([NCT07144293](https://clinicaltrials.gov/study/NCT07144293); planned n ≈ 82; primary Grade ≥2 AE occurrence), childhood cancer survivors ([NCT04733534](https://clinicaltrials.gov/study/NCT04733534); planned n ≈ 110; primary change in walking speed), and mental-illness-associated accelerated aging ([NCT05838560](https://clinicaltrials.gov/study/NCT05838560); planned n ≈ 40; primary completion/tolerability) ask whether intermittent D+Q improves physical function when senescence burden is high. - **Metabolic and fibrotic liver disease:** Phase 1/2 [NCT05506488](https://clinicaltrials.gov/study/NCT05506488) (planned n ≈ 30; primary histologic fibrosis improvement without non-alcoholic fatty liver disease (NAFLD) score worsening at ~21 weeks) evaluates D+Q for fibrotic NAFLD / non-alcoholic steatohepatitis (NASH)—relevant to multi-morbidity longevity goals. - **Bone and skeletal aging follow-on:** Building on Farr et al. 2024 ([PMID 38956196](https://pubmed.ncbi.nlm.nih.gov/38956196/); Phase 2 bone RCT, n = 60), further work tests whether p16-high subgroups reliably benefit and whether fracture or BMD hard endpoints move. - **Adipose single-cell mapping:** Phase 2/3 [NCT05653258](https://clinicaltrials.gov/study/NCT05653258) (planned n ≈ 160; primary insulin sensitivity) pairs senolytic intervention concepts with single-nuclei RNA-seq (RNA sequencing) of adipose tissue to refine cellular targets. - **Potential negative or limiting findings:** [A Popular Senolytic Treatment Causes Brain Damage in Mice](https://www.lifespan.io/a-popular-senolytic-treatment-causes-brain-damage-in-mice/) (Lifespan.io) and related animal work have highlighted possible myelin/oligodendrocyte stress with certain D+Q regimens in aged mice—an example of research that could weaken indiscriminate use if replicated. Null or mixed human endpoints (bone primary endpoint overall null; AD cognitive endpoints null in tiny pilots; IPF RCT without clear function gain) already temper early open-label enthusiasm. - **Next-generation senolytics:** Parallel trials of fisetin, BCL-xL inhibitors, and immune-mediated senescent-cell clearance may either complement or supersede D+Q depending on tissue spectrum and safety. ## Conclusion Dasatinib plus quercetin is the prototype intermittent senolytic combination: a leukemia kinase inhibitor paired with a plant flavonoid to disable different survival pathways in senescent cells. Mouse studies link short courses to better physical function and longer remaining life. In humans, small pilots show that brief courses can lower senescent-cell markers in fat and skin and are generally workable under medical supervision. Functional gains in lung fibrosis looked encouraging in an open-label series but were not clearly reproduced in a tiny randomized pilot. A mid-sized bone trial missed its main bone-breakdown goal overall, with hints of benefit only in people who already carried a high senescence signal. Early brain-aging work shows some dasatinib reaches the spinal fluid, while quercetin does not, without proven thinking or memory gains. Risks track the cancer drug more than the supplement: blood-count effects, fluid around the lungs or heart, bleeding, heart rhythm concerns, and many drug interactions through the main liver enzyme that processes dasatinib. Intermittent short courses aim to limit exposure, yet long-term safety of repeated pulses in people without cancer is not established. Evidence is early and uneven—tissue marker signals exist; hard longevity and multi-disease outcome data in proactive adults do not. For health- and longevity-oriented adults, the combination remains an experimental, off-label, clinician-supervised tool with a coherent mechanism and incomplete clinical proof—not a settled rejuvenation regimen. Evidence quality and commercial enthusiasm around aging science deserve weight when interpreting claims. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**